Bio-Rad Laboratories (BIO) Cash from Financing Activities (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Cash from Financing Activities data on file, last reported at -$44.0 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 54.96% year-over-year to -$44.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$229.5 million (up 27.49% YoY) and the FY2025 annual result came in at -$283.2 million, down 29.43% from the prior year.
• Cash from Financing Activities retreated to -$44.0 million in Q1 2026 per BIO's latest filing, from $3.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $1.2 billion in Q1 2022 and bottomed at -$202.7 million in Q2 2023.
• The 5-year median for Cash from Financing Activities is -$69.5 million (2022), against an average of $125000.0.
• Peak annual rise in Cash from Financing Activities reached 2613.98% in 2022, while the deepest fall reached 4334.76% in 2022.
• Tracing BIO's Cash from Financing Activities over 5 years: stood at -$86.6 million in 2022, then tumbled by 131.62% to -$200.6 million in 2023, then jumped by 86.94% to -$26.2 million in 2024, then jumped by 112.6% to $3.3 million in 2025, then sank by 1433.33% to -$44.0 million in 2026.
• Per Business Quant, the three latest BIO Cash from Financing Activities figures stand at -$44.0 million (Q1 2026), $3.3 million (Q4 2025), and -$52.5 million (Q3 2025).

Peer Comparison